Published in Curr Opin Virol on January 04, 2012
Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology (2015) 1.52
Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov (2013) 1.43
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One (2013) 1.16
Integrative functional genomics of hepatitis C virus infection identifies host dependencies in complete viral replication cycle. PLoS Pathog (2014) 1.11
Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses. Antiviral Res (2014) 1.06
Chronic hepatitis C: This and the new era of treatment. World J Hepatol (2016) 0.98
Activation and evasion of antiviral innate immunity by hepatitis C virus. J Mol Biol (2013) 0.96
How viruses use the endoplasmic reticulum for entry, replication, and assembly. Cold Spring Harb Perspect Biol (2013) 0.93
Barriers of hepatitis C virus interspecies transmission. Virology (2013) 0.92
Dual function of CD81 in influenza virus uncoating and budding. PLoS Pathog (2013) 0.92
Live cell imaging of viral entry. Curr Opin Virol (2013) 0.90
Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. Hepatology (2014) 0.88
Hepatitis C virus NS4B targets lipid droplets through hydrophobic residues in the amphipathic helices. J Lipid Res (2013) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
GP73 is upregulated by hepatitis C virus (HCV) infection and enhances HCV secretion. PLoS One (2014) 0.86
Contrasting roles of mitogen-activated protein kinases in cellular entry and replication of hepatitis C virus: MKNK1 facilitates cell entry. J Virol (2013) 0.85
How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol (2014) 0.85
In vivo models of hepatitis B and C virus infection. FEBS Lett (2016) 0.85
Hepatocyte nuclear factor 4α and downstream secreted phospholipase A2 GXIIB regulate production of infectious hepatitis C virus. J Virol (2013) 0.84
Apolipoprotein E, but Not Apolipoprotein B, Is Essential for Efficient Cell-to-Cell Transmission of Hepatitis C Virus. J Virol (2015) 0.82
Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol (2015) 0.82
Oxidative stress modulation in hepatitis C virus infected cells. World J Hepatol (2015) 0.81
Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. Proc Natl Acad Sci U S A (2016) 0.80
Hunting Viral Receptors Using Haploid Cells. Annu Rev Virol (2015) 0.79
Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6. Virology (2014) 0.79
Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus. PLoS Pathog (2016) 0.79
Sigma-1 receptor regulates early steps of viral RNA replication at the onset of hepatitis C virus infection. J Virol (2013) 0.78
Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection. J Virol (2016) 0.78
Pan-genotypic Hepatitis C Virus Inhibition by Natural Products Derived from the Wild Egyptian Artichoke. J Virol (2015) 0.78
Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. PLoS One (2016) 0.76
Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection. J Gen Virol (2015) 0.76
Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients. J Virol (2015) 0.76
The expression of the hepatocyte SLAMF3 (CD229) receptor enhances the hepatitis C virus infection. PLoS One (2014) 0.76
Liver progenitor cell and KDR. Cell Cycle (2014) 0.75
Genetic heterogeneity of hepatitis C virus cell entry receptors seems to have no influence on selection of virus variants. Virol J (2014) 0.75
Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus. Iran J Pathol (2016) 0.75
Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine. Antimicrob Agents Chemother (2014) 0.75
Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection. J Viral Hepat (2016) 0.75
The unexpected structures of hepatitis C virus envelope proteins. Exp Ther Med (2017) 0.75
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med (1999) 16.35
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature (2007) 9.52
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J (2002) 7.93
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology (2002) 4.98
Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell (2006) 4.68
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol (1994) 4.21
Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol (2006) 3.75
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol (2006) 3.33
A genetically humanized mouse model for hepatitis C virus infection. Nature (2011) 3.15
A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol (1998) 3.13
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
Formation of native hepatitis C virus glycoprotein complexes. J Virol (1997) 2.87
Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J Virol (2008) 2.84
The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus. J Hepatol (2006) 2.74
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Hepatitis C and liver transplantation. Nature (2005) 2.53
Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol (1999) 2.52
Hepatitis C virus entry requires a critical postinternalization step and delivery to early endosomes via clathrin-coated vesicles. J Virol (2006) 2.50
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology (2007) 2.25
Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci (2002) 2.10
CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J Virol (2008) 2.09
Diverse CD81 proteins support hepatitis C virus infection. J Virol (2006) 2.07
The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J Virol (1999) 1.97
Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. Hepatology (2010) 1.87
The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One (2008) 1.86
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology (2009) 1.72
Epidermal growth factor receptor activation differentially regulates claudin expression and enhances transepithelial resistance in Madin-Darby canine kidney cells. J Biol Chem (2003) 1.68
Claudin association with CD81 defines hepatitis C virus entry. J Biol Chem (2010) 1.67
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
Mouse hepatic cells support assembly of infectious hepatitis C virus particles. Gastroenterology (2011) 1.64
CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. J Virol (2008) 1.62
Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. Gastroenterology (2010) 1.58
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Effect of cell polarization on hepatitis C virus entry. J Virol (2007) 1.41
Hepatitis C virus infection of neuroepithelioma cell lines. Gastroenterology (2010) 1.35
Towards a small animal model for hepatitis C. EMBO Rep (2009) 1.34
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants. J Virol (2010) 1.33
A novel cysteine cross-linking method reveals a direct association between claudin-1 and tetraspanin CD9. Mol Cell Proteomics (2007) 1.30
Molecular and bioinformatic evidence of hepatitis C virus evolution in brain. J Infect Dis (2008) 1.18
Cerebral dysfunction in chronic hepatitis C infection. J Viral Hepat (2003) 1.13
Assembly of a functional HCV glycoprotein heterodimer. Curr Issues Mol Biol (2007) 1.10
Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol (2010) 1.07
Hepatitis C virus is primed by CD81 protein for low pH-dependent fusion. J Biol Chem (2011) 1.04
Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J Gen Virol (2004) 1.03
Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. J Virol (2010) 1.00
Hepatitis C virus enters human peripheral neuroblastoma cells - evidence for extra-hepatic cells sustaining hepatitis C virus penetration. J Viral Hepat (2010) 0.90
Scavenger receptor class B type I and the hypervariable region-1 of hepatitis C virus in cell entry and neutralisation. Expert Rev Mol Med (2011) 0.88
Complete replication of hepatitis C virus in cell culture. Science (2005) 18.59
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature (2009) 8.05
Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J Virol (2006) 3.71
Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J Virol (2004) 3.39
Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology (2008) 2.91
High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat Methods (2012) 2.62
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A (2012) 2.05
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
Superinfection exclusion in cells infected with hepatitis C virus. J Virol (2007) 1.71
Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A (2007) 1.64
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol (2011) 1.37
Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine (2007) 1.28
Determinants of the hepatitis C virus nonstructural protein 2 protease domain required for production of infectious virus. J Virol (2009) 1.21
Hepatic cells derived from induced pluripotent stem cells of pigtail macaques support hepatitis C virus infection. Gastroenterology (2013) 1.09
Temporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies. PLoS Pathog (2013) 1.08
Species-specific regions of occludin required by hepatitis C virus for cell entry. J Virol (2010) 1.07
KDR identifies a conserved human and murine hepatic progenitor and instructs early liver development. Cell Stem Cell (2013) 1.06
Internal initiation stimulates production of p8 minicore, a member of a newly discovered family of hepatitis C virus core protein isoforms. J Virol (2009) 1.01
HepG2 cells mount an effective antiviral interferon-lambda based innate immune response to hepatitis C virus infection. Hepatology (2014) 0.99
miR-122 is more than a shield for the hepatitis C virus genome. Proc Natl Acad Sci U S A (2013) 0.88
Goal planning: a retrospective audit of rehabilitation process and outcome. Clin Rehabil (2004) 0.88
Transdominant inhibition of bovine viral diarrhea virus entry. J Virol (2007) 0.83
Cryptic impacts of temperature variability on amphibian immune function. J Exp Biol (2013) 0.81
The accelerating pace of HCV research: a summary of the 15th International Symposium on Hepatitis C Virus And Related Viruses. Gastroenterology (2008) 0.79
Hepatitis C virus replicons finally get to second base. Gastroenterology (2003) 0.78
Will there be an HCV meeting in 2020? Summary of the 17th international meeting on hepatitis C virus and related viruses. Gastroenterology (2011) 0.75